Identify H. Pylori with certainty – and with ease.
Untreated infection also increases the risk of stomach cancer.
H. Pylori infection is the most common chronic bacterial infection in the world: more than 50% of the world population suffers from H. Pylori infection.
Our Biocard™ tests are easy to use and highly accurate.
Biocard™ H. Pylori IgG Rapid Test
Biocard™ H. Pylori IgG Rapid Test is an immunochromatographic rapid test for the detection of H. Pylori IgG antibodies from serum or whole blood samples. This noninvasive serological test is useful in first-step screening. It is not interfered by antacid medication or antibiotics, unlike biopsy-based tests, urea breath tests or stool antigen tests that may give false negative results under medication.
- CE marked kits available for both home and professional tests
- Simple and quick test procedure
- Reliable results in less than 10 minutes
- 95.2% sensitivity and 95.5% specificity
- Convenient testing with only one drop of blood (10μl) or serum (5μl)
Biocard™ H. Pylori Urease Test
Biocard™ H. Pylori Urease Test is a tablet test for the qualitative detection of urease activity from biopsy or culture samples. H. Pylori produces urease that hydrolyses urea to ammonia and raises the pH of the medium, changing the color of the medium.
- Test results can be seen in 30 minutes
- Sensitivity 95% and specificity 98.3%
CE approval for sale in Europe.
Please note: Product Specifications are subject to change without prior notice and may include product modifications, improvements or upgrades.
Please check with New Day Diagnostics or your sales rep.
- This product has been authorized by the FDA under an Emergency Use Authoization (EUA)
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.